Start Your Search
Poster Session (ID 8)
- Event: ACLC 2018
- Type: Poster Session
- Presentations: 1
- Coordinates: 11/07/2018, 00:00 - 00:00, Poster Hall
P119 - Impact of Treatment Modality on Long-Term Survival of Small-Cell Lung Cancer with IA Stage: a Population-based Study (ID 39)
00:00 - 00:00 | Author(s): H. Zhou
The purpose of this study is to identify the optimal treatment modality for small-cell lung cancer (SCLC) patients with IA stage (T1N0M0 status).
The Surveilance, Epidemiology and End Results database was used to identify SCLC patients with IA stage who received surgical resection or chemo-radiotherapy (CRT) between January 2004 and December 2014. Surgery program include lobectomy / wedge resection / segmentectomy plus lymphadenectomy (examined lymph node [ELNs] ?1). Propensity score match analysis is utilized to balance the baseline characteristics.
A total of 686 SCLC with IA stage were included; 337 patients received surgery and 349 patients were treated by CRT alone. Patients received surgery presented better outcome than CRT alone, with the 5-year estimated overall survival (OS) of 50.0% and 24.7%, respectively (adjusted HR=0.495, 95%CI, 0.401-0.611). The median survival duration is longer in patients who received lobectomy or extended lymphadenectomy (lobectomy vs. sublobectomy, 67 months vs. 38 months in matched cohort, p=0.223; ELN>7 vs. ELN?7, 91 months vs. 54 months, p=0.105). Additional chemo/radiotherapy is associated with longer survival in patients who received lobectomy. For SCLC patients with IA stage, the best prognosis is observed in patients who received lobectomy plus chemotherapy and radiotherapy and the 5-year survival rate is 73.5% (Figure 1).
Lobectomy plus CRT as a component of treatment is associated with significantly longer survival than other treatment modality and should be considered in the management of SCLC with IA stage.